Bhader Mohammed, Al-Hindi Mohammed, Ghaddaf Abdullah, Alamoudi Anas, Abualola Amal, Kalantan Renad, AlKhulifi Norah, Halawani Ibrahim, Al-Qurashi Mansour
College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah 21423, Saudi Arabia.
King Abdullah International Medical Research Center, Jeddah 22384, Saudi Arabia.
Children (Basel). 2023 Dec 18;10(12):1935. doi: 10.3390/children10121935.
The noninvasive neurally adjusted ventilatory assist (NIV-NAVA) is a newly developed noninvasive ventilation technique with promising clinical and ventilatory outcomes for preterm infants. This systematic review and meta-analysis aimed to investigate whether NIV-NAVA has better clinical and ventilatory outcomes than nasal continuous airway pressure (NCPAP) or noninvasive positive pressure ventilation (NIPP) on premature infants. MEDLINE, Embase, and CENTRAL were searched, and randomized controlled trials (RCTs) that compared NIV-NAVA with NCPAP or NIPP for preterm infants (gestational age: <37 weeks) were included. We evaluated the following outcomes in the neonatal intensive care unit: the desaturation rate, failure of noninvasive modality requiring intubation when received as the primary mode or the need for re-intubation after extubation from mechanical ventilation in the secondary mode (weaning), length of stay, and fraction of inspired oxygen. The mean difference and risk ratio were used to represent continuous and dichotomous outcomes, respectively. We included nine RCTs involving 339 preterm infants overall. NIV-NAVA showed similar clinical and ventilatory outcomes to NCPAP or NIPP, except for the maximum diaphragmatic electrical activity. The rate of failure of the noninvasive modality was not statistically different between NIV-NAVA and NCPAP. The pooled estimates for the maximum electrical activity were significantly reduced in NIV-NAVA compared with those in NIPP. The findings suggest that NIV-NAVA may be as safe and effective as NCPAP and NIPP for preterm neonates, particularly those who may not tolerate these alternative noninvasive methods. However, further trials are recommended for greater evidence.
无创神经调节通气辅助(NIV-NAVA)是一种新开发的无创通气技术,对早产儿具有良好的临床和通气效果。本系统评价和荟萃分析旨在研究NIV-NAVA在早产儿中是否比鼻持续气道正压通气(NCPAP)或无创正压通气(NIPP)具有更好的临床和通气效果。检索了MEDLINE、Embase和CENTRAL,并纳入了将NIV-NAVA与NCPAP或NIPP用于早产儿(胎龄:<37周)的随机对照试验(RCT)。我们在新生儿重症监护病房评估了以下结局:去饱和率、作为主要模式接受时无创模式失败需要插管的情况或在二级模式(撤机)下机械通气拔管后再次插管的需求、住院时间和吸入氧分数。分别用平均差和风险比来表示连续和二分结局。我们纳入了9项RCT,共涉及339名早产儿。除最大膈肌电活动外,NIV-NAVA的临床和通气效果与NCPAP或NIPP相似。NIV-NAVA和NCPAP之间无创模式失败率无统计学差异。与NIPP相比,NIV-NAVA中最大电活动的合并估计值显著降低。研究结果表明,NIV-NAVA对早产新生儿可能与NCPAP和NIPP一样安全有效,尤其是那些可能不耐受这些替代无创方法的新生儿。然而,建议进行进一步试验以获得更多证据。